CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Diadexus Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Diadexus Inc
343 Oyster Point Boulevard
Phone: (650) 246-6400p:650 246-6400 South San Francisco, CA  94080  United Kingdom
This company was the object of a Reverse Acquisition on 7/28/2010.
In July 2010, the Company completed a reverse merger with former diaDexus, Inc., which was the successor to a company initially formed as a joint venture between SmithKlineBeecham Corporation (now GlaxoSmithKline LLC and Incyte Pharmaceuticals, Inc.). Upon formation in September 1997, SmithKlineBeecham Corporation granted former diaDexus, Inc. an exclusive license to certain diagnostic intellectual property, including exclusive rights to develop diagnostic assays for Lp-PLA2. In November 2010, in connection with the reverse merger, the Company changed its name to Diadexus, Inc.
Business Summary
diaDexus, Inc. is a diagnostics company developing and commercializing products that deliver healthcare providers with information to assist in the management of their patients throughout the course of cardiac disease. The Company's capabilities include manufacturing, assay development, Food and Drug Administration (FDA) regulatory clearances, and marketing and selling products. It is engaged in the testing of Lp-PLA2 (lipoprotein-associated phospholipase A2), a cardiovascular risk marker that provides new information, over and above risk factors measured in a lipid panel. It sells diagnostic products to laboratories and promotes these products to the laboratories' sales representatives, as well as directly to healthcare providers to support the laboratory partners' efforts. Its commercially available products consist of The PLAC Test ELISA Kit (the PLAC ELISA Test) and The PLAC Test for Lp-PLA2 Activity (PLAC Activity Test). Its other products include proADM, proET-1 and proANP.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/200112/31/2001YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations
2835 In vitro and in vivo diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Lori F.Rafield 60
CEO, Board Member Brian E.Ward 61
Executive VP & CTO EmiZychlinsky 59
Chief Business Officer MichaelRichey

Business Names
Business Name
DDXS
diaDexus Inc.
diaDexus, Inc.

General Information
Number of Employees: 83 (As of 12/31/2001)
Outstanding Shares: 53,067,057 (As of 5/16/2011)
Shareholders: 282
Stock Exchange: NASD
Federal Tax Id: 770568338


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023